Felodipine-metoprolol combination tablet: a valuable option to initiate antihypertensive therapy?

Details

Ressource 1Download: serval:BIB_093DBBB6F766.P001 (169.70 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_093DBBB6F766
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Felodipine-metoprolol combination tablet: a valuable option to initiate antihypertensive therapy?
Journal
American Journal of Hypertension
Author(s)
Waeber B., Detry  J. M., Dahlof B., Puig  J. G., Gundersen T., Hosie J., Januszewicz W., Lindstrom  C. J., Magometschnigg D., Safar M., Tanser P., Toutouzas P.
ISSN
0895-7061
Publication state
Published
Issued date
1999
Peer-reviewed
Oui
Volume
12
Number
9 Pt 1
Pages
915-20
Language
english
Notes
Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Abstract
The aim of the present study was to assess the efficacy and tolerability of a calcium antagonist/beta-blocker fixed combination tablet used as first-line antihypertesnive therapy in comparison with an angiotensin converting enzyme inhibitor and placebo. Patients with uncomplicated essential hypertension (diastolic blood pressure between 95 and 110 mm Hg at the end of a 4-week run-in period) were randomly allocated to a double-blind, 12-week treatment with either a combination tablet of felodipine and metoprolol (Logimax), 5/50 mg daily (n = 321), enalapril, 10 mg daily (n = 321), or placebo (n = 304), with the possibility of doubling the dose after 4 or 8 weeks of treatment if needed (diastolic blood pressure remaining >90 mm Hg). The combined felodipine-metoprolol treatment controlled blood pressure (diastolic < or =90 mm Hg 24 h after dose) in 72% of patients after 12 weeks, as compared with 49% for enalapril and 30% for placebo. A dose adjustment was required in 38% of patients receiving the combination, in 63% of patients allocated to placebo, and 61% of enalapril-treated patients. The overall incidence of adverse events was 54.5% during felodipine-metoprolol treatment; the corresponding values for enalapril and placebo were 51.7% and 47.4%, respectively. Withdrawal of treatment due to adverse events occurred in 18 patients treated with the combination, in 10 patients on enalapril, and 12 patients on placebo. No significant change in patients' well-being was observed in either of the three study groups. These results show that a fixed combination tablet of felodipine and metoprolol allows to normalize blood pressure in a substantially larger fraction of patients than enalapril given alone. This improved efficacy is obtained without impairing the tolerability. The fixed-dose combination of felodipine and metoprolol, therefore, may become a valuable option to initiate antihypertensive treatment.
Keywords
Administration, OralAdrenergic beta-Antagonists/*therapeutic useAngiotensin-Converting Enzyme Inhibitors/therapeutic useBlood Pressure/drug effectsCalcium Channel Blockers/*therapeutic useDouble-Blind MethodDrug Therapy, CombinationEnalapril/therapeutic useFelodipine/*therapeutic useFemaleHumansHypertension/*drug therapy/physiopathologyMaleMetoprolol/*therapeutic useMiddle AgedTabletsTreatment Outcome
Pubmed
Web of science
Open Access
Yes
Create date
06/03/2009 12:00
Last modification date
25/09/2019 6:08
Usage data